Literature DB >> 7942148

Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation.

G van der Pluijm1, H Mouthaan, C Baas, H de Groot, S Papapoulos, C Löwik.   

Abstract

We investigated possible inhibitory effects of five synthetic Arg-Gly-Asp (RGD)-containing peptides on osteoclastic resorption in three distinct in vitro resorption assays (17-day-old fetal mouse bone organ cultures) that differ in stages of osteoclast differentiation. RGD peptides, which can bind the adhesion receptors called integrins, inhibited osteoclastic resorption (45Ca release) in fetal mouse bone explants in which osteoclast precursors have yet to adhere to the mineralized matrix and develop into mature osteoclasts (metacarpals and coculture system). Treatment of metacarpals with RGD peptides inhibited the formation of multinucleated TRAP+ osteoclasts in the mineralized matrix because their mononuclear TRAP+ osteoclast precursors remained localized in the periosteum. In particular, echistatin, a viper venom protein with known affinity for alpha v beta 3 integrin, and GdRGDSP inhibited osteoclastic resorption dose dependently in these systems (ED50 10(-9) and 10(-4) M, respectively) but did not alter the activity of mature resorbing osteoclasts in radii. In addition, 45Ca release was significantly inhibited by the cyclic peptide GPenGRGDSPCA, which has a relatively higher affinity for the vitronectin than fibronectin receptor(s). In contrast, GRDGdSP, which has a much higher affinity for the fibronectin receptor (than the vitronectin receptors), had no effect on resorption at similar concentrations in any resorption system used. In summary, the data presented in this paper show that peptides with RGD motifs are capable of inhibiting osteoclastic resorption in bone organ cultures. Our studies not only support the hypothesis concerning the importance of alpha v beta 3 in osteoclastic resorption but also suggest an important role of integrin(s) in events preceding the actual resorption of calcified matrix by osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942148     DOI: 10.1002/jbmr.5650090709

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

Authors:  G van der Pluijm; H Vloedgraven; E van Beek; L van der Wee-Pals; C Löwik; S Papapoulos
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.

Authors:  V W Engleman; G A Nickols; F P Ross; M A Horton; D W Griggs; S L Settle; P G Ruminski; S L Teitelbaum
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

3.  Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro.

Authors:  Samir M Abdelmagid; Joyce Y Belcher; Fouad M Moussa; Suzanne L Lababidi; Gregory R Sondag; Kimberly M Novak; Afif S Sanyurah; Nagat A Frara; Roshanak Razmpour; Fabiola E Del Carpio-Cano; Fayez F Safadi
Journal:  Am J Pathol       Date:  2014-01-23       Impact factor: 4.307

4.  A beta 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration.

Authors:  F Meng; C A Lowell
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

5.  Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption.

Authors:  Susan R Wilson; Christoph Peters; Paul Saftig; Dieter Brömme
Journal:  J Biol Chem       Date:  2008-11-21       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.